Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials

    Journal of the American Society of Nephrology Date published:

  • The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

    Kidney International Reports Date published:

  • Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide

    European Heart Journal Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

    Journal of the American Society of Nephrology Date published:

  • Development and Validation of a New Hierarchical Composite Endpoint for Clinical Trials of Kidney Disease Progression

    Journal of the American Society of Nephrology Date published:

  • Targeting APRIL in the Treatment of IgA Nephropathy

    Clinical Journal of the American Society of Nephrology Date published:

  • Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial

    International Journal of Cardiology Date published:

  • Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

    Kidney International Date published:

  • Combination therapy with kidney protective therapies: optimizing the benefits?

    Current Opinion in Nephrology & Hypertension Date published:

  • The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Kidney Function, Albuminuria and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

    American Journal of Kidney Diseases Date published:

  • Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

    Circulation Date published:

  • Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

    Diabetes, Obesity and Metabolism Date published:

  • Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care

    Unknown Date published:

  • Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

    Journal of the American Heart Association Date published: